Heart Failure & Cardiac Repair and Haematopoietic stem-cell transplantation (HSCT): what the trial registry contains

Why this is studied in Heart Failure & Cardiac Repair

Heart failure with reduced ejection fraction involves lost cardiomyocytes and adverse remodelling. Cell therapy has been studied here longer than in almost any other indication, and the arc is instructive: early enthusiasm, mixed later-phase results, and a field that has narrowed its claims from regeneration to modest functional support.

What HSCT means in this table

Haematopoietic transplantation is the oldest and most consequential cell therapy in medicine, with conditioning regimens that carry real mortality risk alongside genuine disease-modifying power. Registrations under this label therefore mix decades-old standard-of-care protocols with newer autoimmune-reset trials, and the risk profile is nothing like that of an outpatient infusion.

The numbers

Every figure below comes from one reproducible query (heart failure x hematopoietic stem cell transplantation) run against ClinicalTrials.gov API v2 on 2026-08-29.

How mature is this evidence?

The ladder is partly climbed: 1 confirmatory-phase records against 13 in total, with the remainder concentrated in dose-finding and safety territory.

6 records are marked completed and 2 ended early (terminated, withdrawn or suspended): 15% of registrations did not run to plan.

Median planned enrolment is 40 participants (largest single study: 159). Trials of this size can describe safety and generate hypotheses; detecting a modest clinical benefit reliably usually needs substantially larger numbers with a control group.

Where the studies are

Across 14 countries with registered sites, United States dominates at roughly 35% — a concentration driven by funding and regulation rather than by clinical outcome.

Legal pathway differs by country — see where cell therapy is legal, by country.

Who runs them

Funding profile: 2 academic or hospital sponsors against 5 commercial ones — commercial overall, which is worth knowing before reading any single positive report.

• M.D. Anderson Cancer Center — 2 records
• Affiliated Hospital to Academy of Military Medical Sciences — 1 record
• Columbia University — 1 record
• Naofumi Takehara — 1 record
• Annetine Gelijns — 1 record
• Pierre Fabre Medicament — 1 record

Representative registered studies

Recruiting studies first, then the most advanced phases. Each identifier links to the registry record, where eligibility criteria, outcome measures and contacts are published.

What this page does and does not tell you

Registration counts measure activity, not effect. A study appears here the moment it is registered — before any participant is enrolled, and regardless of whether results are ever posted.

If a clinic offers you this today, the useful question is not "is there research?" but "which of these registered studies is mine part of, and if none, what evidence applies to the exact product I am being sold?" The Provider Question Builder turns that into a scored checklist.

Frequently asked

How many HSCT studies for Heart Failure & Cardiac Repair are recruiting right now?

1 of 13 registered records were listed as recruiting in the 2026-08-29 snapshot. Recruitment status changes frequently; the registry record is authoritative.

Is HSCT an approved treatment for Heart Failure & Cardiac Repair?

Registration on ClinicalTrials.gov is not approval. Approval is granted by a regulator for a specific product and indication after review of submitted evidence. 13 registered studies tell you research exists, not that a product cleared review.

How advanced is the research on HSCT for Heart Failure & Cardiac Repair?

1 of 13 records carry a Phase 3 or Phase 4 label and 6 are marked completed. Registrations run from 2006 to 2020.

Registry and literature counts retrieved 2026-08-29 (ClinicalTrials.gov API v2; PubMed E-utilities). Registration or publication volume measures research activity, not effectiveness or approval. Educational information — not medical advice; verify product, indication, legal pathway and evidence with an independent qualified physician. Page generated 2026-08-29. See our editorial standards.